| Literature DB >> 35231421 |
Maxime Meylan1, Florent Petitprez2, Etienne Becht3, Antoine Bougoüin1, Guilhem Pupier1, Anne Calvez1, Ilenia Giglioli1, Virginie Verkarre4, Guillaume Lacroix1, Johanna Verneau1, Chen-Ming Sun1, Pierre Laurent-Puig5, Yann-Alexandre Vano6, Reza Elaïdi7, Arnaud Méjean8, Rafaël Sanchez-Salas9, Eric Barret9, Xavier Cathelineau9, Stephane Oudard10, Claude-Agnès Reynaud11, Aurélien de Reyniès12, Catherine Sautès-Fridman1, Wolf Herman Fridman13.
Abstract
The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial transcriptomics to examine the nature of B cell responses within TLS in renal cell carcinoma (RCC). B cells were enriched in TLS, and therein, we could identify all B cell maturation stages toward plasma cell (PC) formation. B cell repertoire analysis revealed clonal diversification, selection, expansion in TLS, and the presence of fully mature clonotypes at distance. In TLS+ tumors, IgG- and IgA-producing PCs disseminated into the tumor beds along fibroblastic tracks. TLS+ tumors exhibited high frequencies of IgG-producing PCs and IgG-stained and apoptotic malignant cells, suggestive of anti-tumor effector activity. Therapeutic responses and progression-free survival correlated with IgG-stained tumor cells in RCC patients treated with immune checkpoint inhibitors. Thus, intratumoral TLS sustains B cell maturation and antibody production that is associated with response to immunotherapy, potentially via direct anti-tumor effects.Entities:
Keywords: B cell maturation; B cell repertoire; Visium; anti-tumor IgG; fibroblasts; plasma cells; renal cell cancer; response to immune check point inhibition; spatial transcriptomics; tertiary lymphoid structures; tumor microenvironment
Mesh:
Substances:
Year: 2022 PMID: 35231421 DOI: 10.1016/j.immuni.2022.02.001
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745